advanced search

Double Bond Pharmaceuticals

Double Bond Pharmaceutical uses its proprietary drug delivery technology, BeloGal for the development of treatments for cancer, infectious diseases and other therapeutic indications. BeloGal formulations target diseased organs and are delivered intravenously or subcutaneously.


Headquarters
Double Bond Pharmaceutical International AB
Virdings allé 32B
75 450 Uppsala
Sweden

Phone / Contact

T: +46 76 164 9917

Authors and Contacts

Dr Iulia Karlsson
Regulatory Affairs Specialist
Double Bond Pharmaceuticals

Article

EXPERT VIEW
Dr Iulia Karlsson
INJECTABLE DRUG DELIVERY: DEVICES MEET NEXT-GENERATION FORMULATIONS
Iulia Karlsson, discusses a new technology called BeloGal which allows drugs to be delivered in high doses to the right organ and avoids the problems of low water solubility that hamper many modern formulations.
Top